Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

• Status: Completed
• Trial end date: 0000-00-00
• Target enrollment: 50
• Participant gender: Both

Summary

The purpose of this study is to assess the long term safety, tolerability, and immunogenicity of ACC-001, an investigational active immunization product+, in subjects with mild to moderate Alzheimer's disease.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Collaborator: JANSSEN Alzheimer Immunotherapy Research & Development, LLC
• Treatments: QS 21
• Last Updated: 2014-01-29

Criteria

Inclusion Criteria:

• Subjects randomized under previous 3134K1-200 study (NCT00479557) and met all inclusion/and none of the exclusion criteria

• Screening brain MRI scan is consistent with the diagnosis of AD ' Mini-Mental State Examination (MMSE) score =10

Exclusion Criteria:

• Significant Neurological Disease other than Alzheimer's disease

• Brain MRI evidence of vasogenic edema (VE) during the preceding 3134K1 200 study (NCT00479557)

• Clinically significant systemic illness